4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019)
4D Molecular Therapeutics (FDMT) posted quarterly Preferred Stock Liabilities of $103.0 million for Q4 2019.
4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Preferred Stock Liabilities for 1 consecutive years, with $103.0 million the latest figure, recorded in Q4 2019.
- In Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $103.0 million; the TTM figure through Dec 2019 stood at $103.0 million (changed N/A YoY), while the FY2019 annual figure was $103.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $103.0 million in Q4 2019 per FDMT's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $103.0 million in Q4 2019 and bottomed at $103.0 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 102.98 Mn |